We confirmed Gly12Asp as the most frequent KRAS mutation, present in 23.9% of our CRC series, and with reported frequency in recent multicenter studies of 19.2% [9], 37.5% [23], and 33.1% [24], respectively. This evidence concerns the gene KRAS and colorectal carcinoma.